Communications Advances Present Challenges to Manufacturers - Social media use raises questions about applying old standards to new information technology. - BioPharm International

ADVERTISEMENT

Communications Advances Present Challenges to Manufacturers
Social media use raises questions about applying old standards to new information technology.


BioPharm International
Volume 25, Issue 3, pp. 14-17

MORE THORNY ISSUES

These kinds of limits on pharma company Internet and social media communications raises concerns about broader curbs on industry use of modern communications technology for a broad range of corporate and operational functions, such as reporting corporate news and developments, recruiting patients for clinical trials, or operating hot lines to receive consumer questions and comments.

Social media appears to have great potential for expanding public reporting of adverse drug events, for example. FDA posts online forms for collecting adverse events under its MedWatch program, but the form is long, detailed, and not widely used. Because consumers already turn to social media to discuss experiences with drugs and biotech therapies, as noted in the Pew study, there's interest in imbedding an adverse event reporting "widget" into social media sites to encourage wider public reporting of drug use problems.

Manufacturers are leery of such initiatives, because they would have to scour Twitter and Facebook and other sites to identify such reports and respond to them, which could be a monumental task. Even with a common format, many publicly reported adverse events would be useless if they fail to clearly identify the patient, reporter, dosage, and type of event. Furthermore, as noted above, a pharmaceutical company still would be constrained in addressing misleading adverse-event reports, especially those involving off-label use.

The Internet has become essential for gaining access to health information, said Jeffrey Francer, assistant general counsel at the Pharmaceutical Research and Manufacturers of American (PhRMA), at the CBI conference. FDA has a Facebook page and uses Twitter to discuss new product approvals. Regulators and manufacturers use blogs and social media to alert the public to product recalls and safety issues. As these activities expand, industry needs a way to ensure the accuracy of information posted online about company operations and products, and to correct misleading or fraudulent postings.

Jill Wechsler is BioPharm International's Washington editor, Chevy Chase, MD, 301.656.4634,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines
Source: BioPharm International,
Click here